UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 05)*

	BioSante Pharmaceuticals, Inc
	(Name of Issuer)
	Common Stock, \$0.0001 Par Value
	(Title of Class of Securities)
	09065 V 20 3
	(CUSIP Number)
	December 31, 2006
	(Date of Event which Requires Filing of this Statement)
Check the appropri	ate box to designate the rule pursuant to which this Schedule is filed:
[] R	tule 13d-1(b) tule 13d-1(c)
	tule 13d-1(d)
	f this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and amendment containing information which would alter the disclosures provided in a prior cover page.
	quired on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the
notes).	
	SCHEDULE 13G CUSIP No. 09065 V 20 3
	COSIT 140. 05003 V 20 3
1.	Names of Reporting Persons. Victor A. Morgenstern
	I.R.S. Identification Nos. of above persons (entities only).
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) [] (b) []
3.	SEC USE ONLY
4.	Citizenship or Place of Organization United States of America
Number of Shares	5. Sole Voting Power 574,571 (see Item 4)
Beneficially	5/4,5/1 (See Rein 4)
Owned by Each Reporting Person With:	6. Shared Voting Power 133,281 (see Item 4)
	7. Sole Dispositive Power 574,571 (see Item 4)

		8. Shared Dispositive Power 133,281 (see Item 4)
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 707,852 (see Item 4)
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) []
	11.	Percent of Class Represented by Amount in Row (9) 3.1%
	12.	Type of Reporting Person IN
		2
Item 1.	Name o	f Issuer
(a)	Naille 0	i issuei
		ne of the Issuer is BioSante Pharmaceuticals, Inc.
(b)	Address	of Issuer's Principal Executive Offices
	The add	ress of the principal executive offices of BioSante is 111 Barclay Boulevard, Lincolnshire, Illinois 60069.
Item 2.		
(a)	Name o	f Person Filing
	This Ar	nendment No. 5 to Schedule 13G is being filed by and on behalf of Victor A. Morgenstern.
(b)		of Principal Business Office or, if none, Residence
	The add	ress of Mr. Morgenstern's principal place of business is 106 Vine Avenue, Highland Park, IL 60035.
(c)	Citizens	
	Mr Mo	rgenstern is a United States citizen.
(d)		Class of Securities
()	The cla	ass of equity securities to which this Statement relates is the common stock, \$0.0001 par value per share, of BioSante
(0)		ceuticals, Inc. Number
(e)		
	The CU	SIP number of the common stock is 09065 V 20 3.
Item 3.	If this s	tatement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)		roker or dealer registered under section 15 of the Act (15 U.S.C. 780).
(b)		ank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	[] Ir	surance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	[] Ir	vestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
(e)		n investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)		n employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)		parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)		savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act
(i)	O	1940 (15 U.S.C. 80a-3);
(j)	į j G	roup, in accordance with §240.13d-1(b)(1)(ii)(J).
Item 4	Owners	chin

Amount beneficially owned: (a)

> Amount beneficially owned: Mr. Morgenstern's beneficial ownership includes: (1) 455,571 shares of common stock; (2) 76,500 shares of common stock issuable upon exercise of a warrant; (3) 42,500 shares of common stock issuable upon exercise of stock options exercisable

within 60 days; (4) 70,000 shares of common stock held by Mr. Morgenstern's wife, as to which shares Mr. Morgenstern disclaims beneficial ownership; and (6) 63,281 shares of common stock held by Resolute Partners. Mr. Morgenstern is a partner of Resolute Partners.

(b) Percent of class:

Percent of class: 3.1%. The foregoing percentage is calculated based on the 22,975,040 shares of common stock reported to be outstanding by BioSante on its most recently filed quarterly report on Form 10-Q for the quarter ended September 30, 2006.

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote

574,571

(ii) Shared power to vote or to direct the vote

133,281

(iii) Sole power to dispose or to direct the disposition of

574,571

(iv) Shared power to dispose or to direct the disposition of

133,281

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Instruction: Dissolution of a group requires a response to this item.

Not Applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group

Item 10. Certifications

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: January 25, 2007

Victor A. Morgenstern

By: /s/ Victor A. Morgenstern

Victor A. Morgenstern